China GDP grows 5% in Q1, beats expectations on exports, spending strength
Here’s a roundup of the most significant insider buying and selling activity disclosed on Tuesday for U.S. publicly traded companies.
Top buys
Lipocine Inc. (NASDAQ:LPCN) saw Director John W. Higuchi acquire 40,000 shares of common stock on April 7, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were purchased at a price of $2.03, totaling $81,199. Following the transaction, Higuchi directly owns 203,797 shares of the $14.4 million market cap biotech company. The purchase comes as the stock trades near its 52-week low of $1.81, having plunged 75% over the past week. According to InvestingPro analysis, the stock appears undervalued at current levels, with an InvestingPro Tip noting the RSI suggests oversold territory.
Contango Silver & Gold Inc. (EXCHANGE:CTGO) received a vote of confidence from Director Nauman Clynton R., who acquired 10,000 shares on April 1, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were purchased at a price of $18.56, for a total transaction value of $185,600. Following the transaction, Nauman directly owns 24,550 shares of Contango Silver & Gold Inc. In other recent developments, Contango Ore Inc. reported a substantial earnings miss for the fourth quarter of 2025, posting an earnings per share of -$4.22, which was significantly below the projected EPS of -$0.0067.
Lamb Weston Holdings Inc (NYSE:LW) saw Director Peter J. Bensen purchase 5,000 shares on April 6, 2026, at a price of $39.445 per share. The total value of the purchase was $197,225. The stock currently trades at $40.58, near its 52-week low of $37.62, following a 36% decline over the past six months. Following the transaction, Bensen directly owns 20,492.7 shares of Lamb Weston Holdings, Inc., which includes 346.7 additional shares acquired through a dividend reinvestment feature since the date of the last report. Bensen also indirectly owns 17,204 shares through a revocable trust. According to InvestingPro analysis, the company currently appears overvalued relative to its Fair Value, though it has raised its dividend for 9 consecutive years with a current yield of 3.78%.
Fuller H B Co (NYSE:FUL) President and CEO Mastin Celeste Beeks acquired 5,170 shares of common stock on April 7, 2026, at a price of $57.08, for a total transaction value of $295,103. The purchase came as shares trade at $57.78, near their 52-week low of $47.56, with InvestingPro analysis indicating the stock is undervalued relative to its Fair Value. According to a Form 4 filing with the Securities and Exchange Commission, the transaction increased Beeks’ indirectly held shares to 8,670, which are held by a revocable trust. Beeks also directly holds 32,873 shares of Fuller H B Co. The company has raised its dividend for 33 consecutive years, according to InvestingPro Tips, which offers 5 additional exclusive tips for FUL investors.
Oscar Health, Inc. (NASDAQ:OSCR) Chief Executive Officer Mark T. Bertolini recently purchased 1,000,000 shares of Class A Common Stock at a price of $11.92 per share, for a total value of $11,920,000. The stock has since risen to $12.97, delivering an 11% return over the past week. According to InvestingPro analysis, Oscar Health appears undervalued at current levels, with a Fair Value of $15.87. According to a Form 4 filing with the Securities and Exchange Commission, Bertolini also disposed of 1,000,001 shares of Class A Common Stock at $11.92, for a total value of $11,920,011. These shares were withheld by the issuer to satisfy tax obligations related to the settlement of performance stock units. In addition, 5,733,334 performance stock units were converted into Class A Common Stock. InvestingPro Tips highlight that analysts predict the company will be profitable this year, with earnings per share forecast at $0.77 for 2026.
Top sells
TKO Group Holdings (NASDAQ:TKO) Director Khan Nick sold 9,518 shares of Class A Common Stock on April 6, 2026, for approximately $1.89 million. The sales occurred at prices ranging from $197.39 to $203.84. The stock has delivered a strong 41% return over the past year, though shares currently trade at a P/E ratio of 85.6. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 7, 2025. Following the transactions, Khan Nick directly owns 100,618.418 shares of TKO Group Holdings. According to InvestingPro analysis, TKO appears undervalued at current levels.
Workday, Inc. (NASDAQ:WDAY) saw David A. Duffield, a ten percent owner, sell shares of Class A Common Stock worth approximately $13.9 million on April 6, 2026. The transaction comes as shares trade at $127.51, down 45% over the past six months and near the stock’s 52-week low of $117.76. The sales involved a total of 96,490 shares with prices ranging from $128.9736 to $132.0075.
United Therapeutics (NASDAQ:UTHR) experienced significant insider selling on April 6, 2026, with both top executives reducing their stakes. Martine Rothblatt, Chairperson and CEO, sold a total of $5.3 million in common stock. The sales, executed under a pre-arranged 10b5-1 trading plan, occurred at prices ranging from $552.6475 to $566.0025 per share. The stock has surged 92% over the past year and currently trades at $565.78, though InvestingPro analysis suggests the shares are overvalued relative to its Fair Value. According to a Form 4 filing with the Securities and Exchange Commission, Rothblatt sold shares in multiple tranches across a range of prices.
United Therapeutics (NASDAQ:UTHR) CFO and Treasurer James Edgemond sold 7,351 shares of common stock on April 6, 2026, for approximately $5.58 million. The sales were executed in multiple transactions with prices ranging from $552.7801 to $566.01 per share. The timing of the sale comes as United Therapeutics trades near its 52-week high of $607.89, following a remarkable 92% return over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value. On the same day, Edgemond also exercised stock options to acquire 10,000 shares of United Therapeutics common stock at a price of $135.42, for a total value of $1,354,199.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Chief Human Resources Officer Melissa McLaughlin sold a total of 3,902 shares of common stock on April 2nd and April 6th, 2026. The sales, executed in multiple transactions, resulted in proceeds totaling $1.27 million. On April 2nd, McLaughlin sold 1,615 shares in a series of transactions with prices ranging from $316.61 to $325.49, for a total of $519,014. These sales were to cover minimum statutory tax withholding obligations.
Monitoring insider trading activity can provide valuable insights into how company executives and directors view their firm’s prospects. While insider purchases may signal confidence in a company’s future performance, and sales might suggest the opposite, it’s important to remember that insiders sell for various reasons, including tax obligations, portfolio diversification, or personal financial planning. Investors should consider insider transactions as one of many factors when making investment decisions, rather than relying on them in isolation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.